Opioid-exposed newborns
Prapela has received FDA Breakthrough Device Designation for Neonatal Abstinence Syndrome.
On May 15, 2023, results from a 180-patient study published in JAMA Pediatrics report that Prapela's technology is associated with a reduction in morphine treatment in newborns exposed to opioids.
Apnea of Prematurity (AOP)
When preterm newborns stop breathing for 20 seconds or more, caffeine is prescribed more than any other treatment. Even after caffeine, most newborns continue to experience apneas several times a day. Prapela has been awarded FDA Breakthrough Device Designation and a grant from the NIH Blueprint MedTech program to gain FDA clearance on our pad to improve the treatment of AOP.
Common breathing issues
Many of the most common breathing issues treated in neonatal intensive care units lead to the use of supplemental oxygen to reverse hypoxia. These issues include Respiratory Syncytial Virus (RSV), Bronchopulmonary Dysplasia (BPD), and Respiratory Distress Syndrome (RDS). A study, soon to be published, found improved oxygen uptake in ventilated newborns while lying on a pad with Prapela's vibration.